Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Oncolytics Biotech Inc's Business Segments
Oncolytics Biotech Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Description of Oncolytics Biotech Inc
Oncolytics Biotech Inc is a Canada-based biotechnology company that focuses on the development of oncolytic viruses as potential cancer treatments. The company was founded in 1998 by Dr. Matt Coffey and is headquartered in Calgary, Alberta.
Oncolytics Biotech's key area of expertise lies in the field of oncolytic virotherapy, which involves the use of genetically modified viruses to selectively target and destroy cancer cells while leaving healthy cells unharmed. The company's flagship product is REOLYSIN, a proprietary formulation of the reovirus that has been engineered to enhance its cancer-killing potential.
REOLYSIN works by infecting cancer cells via a receptor known as junctional adhesion molecule A (JAMA). Once inside the cancer cell, the reovirus replicates, causing the cancer cell to burst and release viral particles. This process leads to the destruction of the cancer cell and the production of more viruses, which can then infect neighboring cancer cells. Importantly, the reovirus is unable to replicate in normal, healthy cells, making it a promising and targeted therapy for cancer treatment.
Oncolytics Biotech has conducted extensive preclinical and clinical trials to evaluate the safety and efficacy of REOLYSIN. These trials have demonstrated the ability of the reovirus to selectively infect and kill a wide range of cancer cells, including those from various solid tumors and hematological malignancies.
In addition to REOLYSIN, Oncolytics Biotech is actively engaged in research and development efforts to identify and develop other oncolytic viruses for potential cancer treatments. The company has a portfolio of intellectual property assets, including patents and patent applications, related to various oncolytic viruses and their uses.
Oncolytics Biotech has collaborations and partnerships with other pharmaceutical and biotechnology companies to advance the development and commercialization of its oncolytic virus therapies. The company has also established relationships with academic institutions and research organizations to further expand its research capabilities and gain access to cutting-edge technologies.
Overall, Oncolytics Biotech Inc is a leading player in the field of oncolytic virotherapy, focused on harnessing the potential of oncolytic viruses to revolutionize cancer treatment. The company's innovative approach and extensive research efforts hold significant promise for the development of effective and targeted therapies for a wide range of cancers.
Oncolytics Biotech's key area of expertise lies in the field of oncolytic virotherapy, which involves the use of genetically modified viruses to selectively target and destroy cancer cells while leaving healthy cells unharmed. The company's flagship product is REOLYSIN, a proprietary formulation of the reovirus that has been engineered to enhance its cancer-killing potential.
REOLYSIN works by infecting cancer cells via a receptor known as junctional adhesion molecule A (JAMA). Once inside the cancer cell, the reovirus replicates, causing the cancer cell to burst and release viral particles. This process leads to the destruction of the cancer cell and the production of more viruses, which can then infect neighboring cancer cells. Importantly, the reovirus is unable to replicate in normal, healthy cells, making it a promising and targeted therapy for cancer treatment.
Oncolytics Biotech has conducted extensive preclinical and clinical trials to evaluate the safety and efficacy of REOLYSIN. These trials have demonstrated the ability of the reovirus to selectively infect and kill a wide range of cancer cells, including those from various solid tumors and hematological malignancies.
In addition to REOLYSIN, Oncolytics Biotech is actively engaged in research and development efforts to identify and develop other oncolytic viruses for potential cancer treatments. The company has a portfolio of intellectual property assets, including patents and patent applications, related to various oncolytic viruses and their uses.
Oncolytics Biotech has collaborations and partnerships with other pharmaceutical and biotechnology companies to advance the development and commercialization of its oncolytic virus therapies. The company has also established relationships with academic institutions and research organizations to further expand its research capabilities and gain access to cutting-edge technologies.
Overall, Oncolytics Biotech Inc is a leading player in the field of oncolytic virotherapy, focused on harnessing the potential of oncolytic viruses to revolutionize cancer treatment. The company's innovative approach and extensive research efforts hold significant promise for the development of effective and targeted therapies for a wide range of cancers.
Oncolytics Biotech Inc. is a biotechnology company focused on the development of oncolytic virus therapies for cancer treatment. The core of its therapeutic approach involves leveraging the immune system to combat tumor cells, thereby providing a promising avenue for cancer treatment. The company primarily focuses on its lead product candidate, REOLYSIN, which is based on a proprietary formulation of the reovirus.
Key Segments
1. Oncolytic Virus Therapeutics:
- Oncolytics Biotech’s primary segment revolves around oncolytic viruses, which are engineered viruses that selectively infect and kill cancer cells while sparing normal cells. This technology serves as a novel therapeutic strategy in oncology.
2. Immuno-oncology:
- The companys approach intersects closely with immuno-oncology, where treatments not only directly target tumor cells but also enhance the bodys immune response against those cells. The immunogenic effects of their viral therapy play a pivotal role in boosting overall anti-tumor activity.
3. Collaborative Research and Development:
- Oncolytics Biotech collaborates with various academic institutions and pharmaceutical companies for research and clinical trials, creating partnerships that enhance the development of their therapies and broaden their potential applications.
Products
1. REOLYSIN (Pelareorep):
- Mechanism of Action: REOLYSIN is a formulation of the reovirus designed to selectively infect and lyse tumor cells. The virus exploits mutations found in many cancers to replicate within and destroy cancerous tissues.
- Clinical Applications: REOLYSIN is being studied in combination with various standard-of-care therapies such as chemotherapy, immunotherapy, and radiation to enhance therapeutic outcomes in multiple cancer types, including but not limited to breast, pancreatic, and head and neck cancers.
- Clinical Trials: The company has been involved in several clinical trials aimed at evaluating the safety and efficacy of REOLYSIN in combination with other treatments, evaluating different cancer types and stages.
2. Combination Therapies:
- Oncolytics Biotech is exploring the combination of REOLYSIN with various immuno-oncology agents, such as checkpoint inhibitors. This is based on the premise that oncolytic viruses can potentially enhance the efficacy of immune checkpoint blockade therapies by increasing the visibility of tumor cells to the immune system.
3. Next Generation Viral Therapeutics:
- The company is also focused on the research into new oncolytic viruses or improved formulations of existing viruses that may exhibit enhanced efficacy, reduced toxicity, or broader application.
Services
1. Clinical Development Services:
- Oncolytics Biotech engages in extensive clinical development services, which include designing and conducting clinical trials aimed at evaluating the safety and efficacy of its therapies. This includes phase I to phase III trials that assess various endpoints critical for regulatory approval.
2. Regulatory Affairs:
- The company has expertise in navigating the regulatory landscape required for bringing novel therapies to market. This includes interaction with health authorities to obtain necessary approvals for clinical trials and product commercialization.
3. Collaborative Partnerships:
- Oncolytics Biotech partners with academic institutions, biotech, and pharmaceutical companies to facilitate research and development efforts. These collaborations may take forms such as co-development agreements, clinical trial partnerships, and joint research initiatives.
4. Educational Initiatives:
- The company may also engage in educational campaigns to inform healthcare professionals about the potential of oncolytic virus therapies and their applications in oncology, aiming to foster a deeper understanding and acceptance of such innovative treatments in clinical practice.
Research and Development
Oncolytics Biotech is committed to continuous research and innovation in oncolytic virotherapy. Ongoing research initiatives are aimed at understanding the mechanisms of action of REOLYSIN, exploring the therapeutic impact on various cancers, and investigating combination therapies to maximize treatment efficacy. The companys R&D pipeline is likely to evolve with emerging scientific discoveries and technological advancements, focusing on maximizing the potential of its viral therapies in oncology.
Overall, Oncolytics Biotech Inc. represents a dynamic player in the biotechnology landscape with a focused therapeutic approach that combines the principles of oncolytic virotherapy and immuno-oncology, underpinned by a commitment to research and clinical advancement in the fight against cancer.
Key Segments
1. Oncolytic Virus Therapeutics:
- Oncolytics Biotech’s primary segment revolves around oncolytic viruses, which are engineered viruses that selectively infect and kill cancer cells while sparing normal cells. This technology serves as a novel therapeutic strategy in oncology.
2. Immuno-oncology:
- The companys approach intersects closely with immuno-oncology, where treatments not only directly target tumor cells but also enhance the bodys immune response against those cells. The immunogenic effects of their viral therapy play a pivotal role in boosting overall anti-tumor activity.
3. Collaborative Research and Development:
- Oncolytics Biotech collaborates with various academic institutions and pharmaceutical companies for research and clinical trials, creating partnerships that enhance the development of their therapies and broaden their potential applications.
Products
1. REOLYSIN (Pelareorep):
- Mechanism of Action: REOLYSIN is a formulation of the reovirus designed to selectively infect and lyse tumor cells. The virus exploits mutations found in many cancers to replicate within and destroy cancerous tissues.
- Clinical Applications: REOLYSIN is being studied in combination with various standard-of-care therapies such as chemotherapy, immunotherapy, and radiation to enhance therapeutic outcomes in multiple cancer types, including but not limited to breast, pancreatic, and head and neck cancers.
- Clinical Trials: The company has been involved in several clinical trials aimed at evaluating the safety and efficacy of REOLYSIN in combination with other treatments, evaluating different cancer types and stages.
2. Combination Therapies:
- Oncolytics Biotech is exploring the combination of REOLYSIN with various immuno-oncology agents, such as checkpoint inhibitors. This is based on the premise that oncolytic viruses can potentially enhance the efficacy of immune checkpoint blockade therapies by increasing the visibility of tumor cells to the immune system.
3. Next Generation Viral Therapeutics:
- The company is also focused on the research into new oncolytic viruses or improved formulations of existing viruses that may exhibit enhanced efficacy, reduced toxicity, or broader application.
Services
1. Clinical Development Services:
- Oncolytics Biotech engages in extensive clinical development services, which include designing and conducting clinical trials aimed at evaluating the safety and efficacy of its therapies. This includes phase I to phase III trials that assess various endpoints critical for regulatory approval.
2. Regulatory Affairs:
- The company has expertise in navigating the regulatory landscape required for bringing novel therapies to market. This includes interaction with health authorities to obtain necessary approvals for clinical trials and product commercialization.
3. Collaborative Partnerships:
- Oncolytics Biotech partners with academic institutions, biotech, and pharmaceutical companies to facilitate research and development efforts. These collaborations may take forms such as co-development agreements, clinical trial partnerships, and joint research initiatives.
4. Educational Initiatives:
- The company may also engage in educational campaigns to inform healthcare professionals about the potential of oncolytic virus therapies and their applications in oncology, aiming to foster a deeper understanding and acceptance of such innovative treatments in clinical practice.
Research and Development
Oncolytics Biotech is committed to continuous research and innovation in oncolytic virotherapy. Ongoing research initiatives are aimed at understanding the mechanisms of action of REOLYSIN, exploring the therapeutic impact on various cancers, and investigating combination therapies to maximize treatment efficacy. The companys R&D pipeline is likely to evolve with emerging scientific discoveries and technological advancements, focusing on maximizing the potential of its viral therapies in oncology.
Overall, Oncolytics Biotech Inc. represents a dynamic player in the biotechnology landscape with a focused therapeutic approach that combines the principles of oncolytic virotherapy and immuno-oncology, underpinned by a commitment to research and clinical advancement in the fight against cancer.